Clinical Trial ResultsAMIX announced positive preliminary results from the first 15 patients of its proof-of-concept trial, showing significant and sustained pain reduction.
Market OpportunityThe potential to expand the addressable market beyond pancreatic cancer pain to other visceral cancers and earlier-stage pancreatic cancers could significantly enhance market opportunities.
Technology InnovationAMIX's breakthrough platform technology could transform the field of electrophysiology by detecting neural signals that indicate pain or disease and destroying those nerves at the source.